全文获取类型
收费全文 | 4771篇 |
免费 | 231篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 125篇 |
妇产科学 | 96篇 |
基础医学 | 748篇 |
口腔科学 | 100篇 |
临床医学 | 395篇 |
内科学 | 1072篇 |
皮肤病学 | 49篇 |
神经病学 | 411篇 |
特种医学 | 151篇 |
外科学 | 877篇 |
综合类 | 20篇 |
预防医学 | 310篇 |
眼科学 | 86篇 |
药学 | 340篇 |
中国医学 | 9篇 |
肿瘤学 | 200篇 |
出版年
2022年 | 28篇 |
2021年 | 50篇 |
2020年 | 35篇 |
2019年 | 38篇 |
2018年 | 44篇 |
2017年 | 47篇 |
2016年 | 62篇 |
2015年 | 75篇 |
2014年 | 97篇 |
2013年 | 128篇 |
2012年 | 183篇 |
2011年 | 222篇 |
2010年 | 146篇 |
2009年 | 150篇 |
2008年 | 259篇 |
2007年 | 269篇 |
2006年 | 257篇 |
2005年 | 280篇 |
2004年 | 276篇 |
2003年 | 261篇 |
2002年 | 240篇 |
2001年 | 113篇 |
2000年 | 145篇 |
1999年 | 134篇 |
1998年 | 90篇 |
1997年 | 57篇 |
1996年 | 53篇 |
1995年 | 61篇 |
1994年 | 59篇 |
1993年 | 57篇 |
1992年 | 68篇 |
1991年 | 80篇 |
1990年 | 56篇 |
1989年 | 61篇 |
1988年 | 50篇 |
1987年 | 49篇 |
1986年 | 50篇 |
1985年 | 44篇 |
1984年 | 34篇 |
1983年 | 39篇 |
1982年 | 35篇 |
1981年 | 46篇 |
1980年 | 42篇 |
1979年 | 25篇 |
1978年 | 30篇 |
1977年 | 30篇 |
1976年 | 22篇 |
1975年 | 38篇 |
1973年 | 19篇 |
1961年 | 17篇 |
排序方式: 共有5038条查询结果,搜索用时 15 毫秒
91.
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission 总被引:7,自引:4,他引:7 下载免费PDF全文
Miklos DB Kim HT Miller KH Guo L Zorn E Lee SJ Hochberg EP Wu CJ Alyea EP Cutler C Ho V Soiffer RJ Antin JH Ritz J 《Blood》2005,105(7):2973-2978
Minor histocompatibility antigens (mHAs) are known targets of donor T cells after allogeneic hematopoietic stem cell transplantation (HSCT). In contrast, B-cell responses to mHAs have not been extensively characterized and the clinical significance of antibodies to mHAs is unknown. We tested 121 patients who underwent HSCT and 134 healthy donors for immunoglobulin G (IgG) antibodies against 5 mHAs encoded by genes on the Y chromosome (DBY, UTY, ZFY, RPS4Y, and EIF1AY). Antibodies to at least one H-Y protein developed in 52% of male patients with female donors compared with 8.7% of male patients with male donors (P < .0001), and in 41.4% of healthy females compared with 7.8% of healthy males (P < .0001). H-Y antibodies develop 4 to 12 months after transplantation and persist for long periods. The clinical significance of H-Y antibodies was characterized in 75 male patients with hematologic malignancies who received stem cells from female donors (F --> M HSCT). The presence of H-Y antibodies correlated with chronic graft-versus-host disease (GVHD) by univariate (odds ratio [OR] = 15.5; P < .0001) and multivariable logistic regression analysis (OR = 56.5; P < .0001). Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD. 相似文献
92.
Richards FO Amann J Arana B Punkosdy G Klein R Blanco C Lopez B Mendoza C Domínguez A Guarner J Maguire JH Eberhard M 《The American journal of tropical medicine and hygiene》2007,77(5):878-882
Endosymbionic Wolbachia bacteria inside adult Onchocerca volvulus worms (causing river blindness) are necessary for female worm fertility. We evaluated whether rifampin and/or azithromycin used in a five-day course could kill Wolbachia. In an open-label trial in Guatemala, 73 patients with 134 palpable onchocercal nodules were randomized into four treatment groups: rifampin, azithromycin, a combination of the two drugs, and controls (multivitamins). After five days of antibiotic treatment, all participants received a single dose of ivermectin on day 6. Nine months after treatment, the nodules were removed and the worms were examined. Skin snips to determine microfilariae were obtained at baseline and nine months. There were no significant differences between any of the treatment groups in the condition of the worms in the nodules, the presence of Wolbachia surface protein, or the number of microfilariae in skin. Short courses with these antibiotics will not clear Wolbachia from O. volvulus. 相似文献
93.
Vladimír Džavík MD FSCAI Upendra Kaul MD DM FSCAI Guilio Guagliumi MD Bernard Chevalier MD Peter C. Smits MD Marrianne Stuteville BSC Dong Li MSC Krishnankutty Sudhir MD PhD Eberhard Grube MD FSCAI 《Catheterization and cardiovascular interventions》2013,82(3):E163-E172
The aim of this analysis was to analyze outcomes of patients undergoing Xience V EES treatment of bifurcation lesions, a subset in which treatment is particularly challenging. The SPIRIT V Study provided an evaluation of the Xience V everolimus eluting stent (EES) performance in complex patient and lesion population. The SPIRIT V Single Arm Study enrolled 2700 patients with de novo coronary artery lesions suitable to be optimally treated with a maximum of four planned Xience V EES. Lesion evaluation was by visual assessment. The outcomes of the 492 patients undergoing Xience V EES stenting of ≥1 bifurcation lesion were compared to those with no bifurcation lesion treated. Compared to those without bifurcation treatment, patients with bifurcation treatment were more likely to have multi‐vessel disease (49% vs 40%), left main treatment (3.1% vs 0.9%), more lesions treated (1.5 vs 1.3), calcification (36.4% vs 27.5%), and ostial (17.1% vs 8.2%) and angulated lesions (29.3% vs 21.1%), all P < 0.001. The 30‐day composite rate of death, myocardial infarction (MI), target vessel revascularization (TVR) was 4.3% in patients with bifurcation PCI and 2.2% in those with non‐bifurcation PCI (P = 0.017). At 2 years, this composite event rate was 11.3% and 10.0% in these two groups, respectively (P = 0.403). Rates of cardiac death, MI, target lesion revascularization (TLR), TVR, and ARC defined definite or probable stent thrombosis (0.4% vs 0.9%, P = 0.402) were not significantly different between the two groups. Despite greater patient and lesion complexity, treatment of patients with bifurcation lesions using the Xience V EES in the SPIRIT V prospective Single Arm Study was safe and effective, with low overall event rates that were similar to those without bifurcation lesion treatment. © 2013 Wiley Periodicals, Inc. 相似文献
94.
95.
Model of bicarbonate secretion by resting frog stomach fundus mucosa I. Transepithelial measurements
Silvana Curci Lucantonio Debellis Rossella Caroppo Eberhard Frömter 《Pflügers Archiv : European journal of physiology》1994,428(5-6):648-654
In the present in vitro experiments on gastric fundus mucosa of Rana esculenta we try to define the mechanism of alkaline secretion that is observed in summer frogs in the resting stomach (blockage of HCl secretion by ranitidine, 10–5 mol/l). The transepithelial voltage and the rate of alkalinization (ASR) of an unbuffered gastric lumen perfusate was measured as a function of serosal (and mucosal) fluid composition. ASR was high (0.88±S.E. 0.09 Eq·cm–2·h–1, n=11) during serosal bath perfusion with HCO3
–-Ringer solution, decreased slightly to 0.50±0.07 Eq·cm–2·h–1 (n=6) in HCO3
–-free HEPES-buffered Ringer solution of the same pH, and decreased to approximately 20% when carbonic anhydrase was inhibited by acetazolamide. While replacement of mucosal or serosal Cl– did not — within 1 h — significantly alter ASR, replacement of serosal Na+ in the presence or absence of HCO3
– strongly reduced ASR, and a similar reduction was observed after serosal application of the anion transport inhibitor DIDS (4,4-diisomiocyanatostilbene-2,2-disulphonate, 2·10–4 mol/l), the metabolic poison rotenone (10–5 mol/l), the uncoupler dinitrophenol (10–4 mol/l), and the Na+ pump inhibitor ouabain (10–4 mol/l), while serosal amiloride (10–4 mol/l) had no effect. These data can be accounted for by a model of alkaline secretion that consists of basolateral HCO3
– uptake from the serosal fluid into the cell via a DIDS-inhibitable Na+(HCO3
–)n-cotransporter and HCO3
– secretion from the cell to the gastric lumen via an anionic conductance pathway. Microelectrode experiments on oxyntopeptic cells reported in the subsequent paper suggest that these cells may also be involved in the resting state alkaline secretion. 相似文献
96.
97.
A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle 总被引:4,自引:0,他引:4
Brandenburg B Stockl L Gutzeit C Roos M Lupberger J Schwartlander R Gelderblom H Sauer IM Hofschneider PH Hildt E 《Hepatology (Baltimore, Md.)》2005,42(6):1300-1309
Protein transduction domains (PTDs) have been used to deliver a variety of biologically active cargo across cellular membranes. However the potential of PTDs to mediate transport of nanoparticular structures into the cytoplasm bypassing the endosomal compartment remains unclear. Cell-permeable virus-like particles (VLPs) harboring a marker gene based on hepatitis B virus nucleocaspids were established. Cell permeability was achieved by fusion with translocation motif (TLM)-PTD. Electron and confocal microscopy revealed that these VLPs translocate as complete particles across the plasma membrane and transverse the cytoplasm toward the nucleus. Inhibition of endocytosis did not affect translocation of these VLPs into the cytoplasm. Based on these particles, a gene transfer system was developed. To this end the particles were loaded with DNA-encoding small hepatitis B virus surface antigen (SHBs) or green fluorescence protein (eGFP) that served as marker genes. Although the DNA-packaging efficiency was very low, applying the appropriate number of VLPs to primary human hepatocytes a gene transfer efficiency of approximately 95% was observed. In conclusion, the TLM-PTD has the potential to mediate efficient transfer of assembled particles and its cargo, nucleic acids, into primary human hepatocytes. This provides the basis for development of novel transducible therapeutic or diagnostic particles. 相似文献
98.
Initial experience with paclitaxel-coated stents 总被引:5,自引:0,他引:5
Local delivery of immunosuppressive or antiproliferative agents using a drug-eluting stent is a new technology that is supposed to inhibit in-stent restenosis, thus providing a biological and mechanical solution. This technique is a very promising. To date, several agents have been used, including paclitaxel, QP-2, rapamycin, actinomycin D, dexamethason, tacrolimus, and everolimus. Several studies, published recently or still ongoing, have evaluated these drugs as to their release kinetics, effective dosage, safety in clinical practice, and benefit. These studies include: SCORE (paclitaxel derivative), TAXUS I-VI, ELUTES, ASPECT, DELIVER (paclitaxel), RAVEL, SIRIUS (sirolimus), ACTION (actinomycin), EVIDENT, PRESENT (tacrolimus), EMPEROR (dexamethason), and FUTURE (everolimus). Paclitaxel was one of the first stent-based antiproliferative agents under clinical investigation that provided profound inhibition of neointimal thickening depending on delivery duration and drug dosage. The randomized, multicenter SCORE trail (Quanam stent, paclitaxel-coated) enrolled 266 patients at 17 sites. At 6-month's follow-up, a drop of 83% in stent restenosis using the drug-eluting stent could be achieved (6.4% drug-eluting stent vs 36.9% control group), which was attributable to a remarkable decrease in intimal proliferation. Unfortunately, due to frequent stent thrombosis and side-branch occlusions, the reported 30-day MACE rate was 10.2%. The randomized TAXUS-I safety trial (BSC, NIRx, paclitaxel-coated) also demonstrated beneficial reduction of restenotic lesions at 6-month's follow-up (0% vs 10%) but was associated with the absence of thrombotic events presumably due to less drug dosage. The ongoing TAXUS II-VI trials are addressing additional insight regarding the efficacy of the TAXUS paclitaxel-eluting stent. ASPECT and ELUTES evaluated paclitaxel-coated stents (i.e., Cook and Supra G), including subgroups with different drug dosages. With respect to stent restenosis and neointimal proliferation, both studies demonstrated a clear dose response. The RAVEL and the SIRIUS trials evaluated sirolimus-coated stents (i.e., Cordis, Johnson & Johnson, and Bx VELOCITY stents). Results confirmed the beneficial findings regarding reduction of renarrowing using a drug-eluting stent without any major adverse effects. Although parameters such as drug toxicity, optimal drug dosage, or delayed endothelial healing still need to be evaluated, today's clinical experience indicates that drug-coated stents are extremely beneficial in the interventional treatment of coronary lesions. 相似文献
99.
100.
Boumsell L; Bernard A; Reinherz EL; Nadler LM; Ritz J; Coppin H; Richard Y; Dubertret L; Valensi F; Degos L; Lemerle J; Flandrin G; Dausset J; Schlossman SF 《Blood》1981,57(3):526-530
Tumor cells from eight adult patients with T-cell chronic malignancies were investigated with a series of monoclonal antibodies recognizing T- cell differentiation antigens. This series allowed definition of discrete subpopulations of mature T cells with functional specialization. All six patients with Sezary syndrome and one patient with T-chronic lymphocytic leukemia had cells with the same phenotype as normal helper/inducer T cells, whereas the other patient with T- chronic lymphocytic leukemia had cell with the same phenotype as normal cytotoxic/suppressor T cells. Some clinical manifestations observed in these patients may reflect retention of functional activities by their malignant cells. 相似文献